Celularity Closes Merger with GX Acquisition Corp

Published on: 

Common stock of merged allogeneic cell therapy company to commence trading on the Nasdaq Capital Market as “CELU” on July 19, 2021.

Celularity Inc., a clinical-stage cellular medicine company developing off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced in a July 16, 2021, press statement the closing of a merger with GX Acquisition Corp. (GXGX).

Proceeds from the transaction totaled approximately $138 million. The combined, publicly traded company will be named Celularity, Inc., and its common stock will commence trading on the Nasdaq Capital Market on July 19, 2021, under the ticker symbol “CELU.” Celularity’s management team will continue leading the merged company following this transaction.

“Celularity aims to transform the way we approach the treatment of cancer and other diseases by harnessing the versatility, unique immune biology and innate stemness of placental-derived cells,” said Robert J. Hariri, founder, chairperson and chief executive officer of Celularity in the press statement. “We are immensely proud of our clinical development results so far as well as the state-of-the-art manufacturing capabilities we built to support rapid scaling and a competitive cost structure for our placental-derived cell therapeutics. We believe off-the-shelf, allogeneic cell therapies will drive a paradigm shift in how clinicians approach the treatment of cancer and other serious diseases.”

“Our PIPE is led by existing Celularity investors, who understand the company’s pipeline and clinical development program and took advantage of the opportunity to add to their investment in Celularity.”Hariri also noted, “ Celularity has entered into important strategic and commercial partnerships with leaders like Palantir and Arthrex which we believe will strengthen our intellectual property and grow revenues from its existing marketed products.”


Dean C. Kehler, co-chairman and CEO of GX Acquisition Corp. and new board member of Celularity, added, “We are excited to see Celularity take this very important next step in its evolution as a transformative biotechnology company by becoming a publicly-traded company, listed on The Nasdaq Capital Market under the symbol “CELU”. This step will enable Celularity to continue to leverage the company’s commercial and clinical stage assets to treat diseases of high unmet need, like cancer, infectious diseases and degenerative diseases.”

The company reported the following details about the transaction in the press statement: “On January 8, 2021, Celularity, a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum placenta, entered into a definitive business combination agreement with GX Acquisition Corp., a special purpose acquisition company (SPAC). Under the terms of the business combination agreement, the SPAC Sponsors and certain current equity holders, officers and directors of Celularity have agreed to be subject to a one-year lockup in respect of their common stock, in each case subject to certain customary exceptions, which will provide important stability to the leadership and governance of the combined entity.”

Source: Celularity